| Literature DB >> 30146778 |
Amirhossein Bahreyni1,2, Amir Avan3,4, Mohammad Shabani5, Mikhail Ryzhikov6, Hamid Fiuji7, Saman Soleimanpour8, Majid Khazaei3,9, Seyed Mahdi Hassanian3,10,11.
Abstract
Adenosine and its analogs are of particular interest as potential therapeutic agents for treatment of cardiovascular diseases (CVDs). A2 adenosine receptor subtypes (A2a and A2b) are extensively expressed in cardiovascular system, and modulation of these receptors using A2 adenosine receptor agonists or antagonists regulates heart rate, blood pressure, heart rate variability, and cardiovascular toxicity during both normoxia and hypoxia conditions. Regulation of A2 adenosine receptor signaling via specific and novel pharmacological regulators is a potentially novel therapeutic approach for a better understanding and hence a better management of CVDs. This review summarizes the role of pharmacological A2 adenosine receptor regulators in the pathogenesis of CVDs.Entities:
Keywords: A2 adenosine receptor; cardiovascular diseases; pharmacological inhibitors
Year: 2018 PMID: 30146778 DOI: 10.1002/jcp.27161
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384